Tracy Saxton
Algemeen Directeur bij Aucupo Biosciences, Inc.
Actieve functies van Tracy Saxton
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
The Damon Runyon Cancer Research Foundation
 The Damon Runyon Cancer Research Foundation Miscellaneous Commercial ServicesCommercial Services The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY. | Corporate Officer/Principal | - | - |
Aucupo Biosciences, Inc.
 Aucupo Biosciences, Inc. BiotechnologyHealth Technology Aucupo Biosciences, Inc. is engaged in biotechnology services. The company was founded by Tracy Saxton and is headquartered in Seattle, WA. | Algemeen Directeur | - | - |
| Oprichter | - | - |
Loopbaan van Tracy Saxton
Eerdere bekende functies van Tracy Saxton
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Dolby Family Ventures LLC
 Dolby Family Ventures LLC Investment ManagersFinance Dolby Family Ventures (Dolby) is a venture capital firm founded in 2013. The firm is headquartered in San Francisco, California. | Private Equity Investor | 01-02-2020 | 30-06-2022 |
Lengo Therapeutics, Inc.
 Lengo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA. | Directeur/Bestuurslid | 01-02-2019 | 31-12-2021 |
| Algemeen Directeur | 01-02-2019 | - | |
Pivotal Bioventure Partners Investment Advisor LLC
 Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | Private Equity Investor | 01-01-2017 | 31-12-2017 |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Directeur/Bestuurslid | 05-09-2017 | 01-12-2017 |
Roche Ventures
 Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | Private Equity Investor | 01-01-2015 | 31-01-2017 |
Cyterix Pharmaceuticals, Inc.
 Cyterix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cyterix Pharmaceuticals, Inc. develops cancer therapeutics. It develops cancer therapeutics based on a proprietary OncoCY prodrug discovery approach. The company was founded by Paul R. Ortiz De Montellano, Luis Bayol and Steven A. Everett on April 10, 2010 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | - | - |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - | - |
| ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Opleiding van Tracy Saxton
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| Simon Fraser University | Undergraduate Degree |
| University of Toronto | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 17 |
| Canada | 3 |
| Zwitserland | 2 |
Operationeel
| Corporate Officer/Principal | 7 |
| Director/Board Member | 6 |
| Private Equity Investor | 3 |
Sectoraal
| Health Technology | 13 |
| Consumer Services | 4 |
| Finance | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| GERON CORPORATION | Health Technology |
| VAXCYTE, INC. | Health Technology |
| Bedrijven in privébezit | 14 |
|---|---|
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Cyterix Pharmaceuticals, Inc.
Cyterix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cyterix Pharmaceuticals, Inc. develops cancer therapeutics. It develops cancer therapeutics based on a proprietary OncoCY prodrug discovery approach. The company was founded by Paul R. Ortiz De Montellano, Luis Bayol and Steven A. Everett on April 10, 2010 and is headquartered in San Francisco, CA. | Health Technology |
Millendo Therapeutics US, Inc.
 Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
The Damon Runyon Cancer Research Foundation
The Damon Runyon Cancer Research Foundation Miscellaneous Commercial ServicesCommercial Services The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY. | Commercial Services |
Roche Ventures
Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | Finance |
PanOptica, Inc.
 PanOptica, Inc. Pharmaceuticals: MajorHealth Technology PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ. | Health Technology |
MISSION Therapeutics Ltd.
 MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Rempex Pharmaceuticals, Inc.
 Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Health Technology |
Dolby Family Ventures LLC
Dolby Family Ventures LLC Investment ManagersFinance Dolby Family Ventures (Dolby) is a venture capital firm founded in 2013. The firm is headquartered in San Francisco, California. | Finance |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | Finance |
Aucupo Biosciences, Inc.
Aucupo Biosciences, Inc. BiotechnologyHealth Technology Aucupo Biosciences, Inc. is engaged in biotechnology services. The company was founded by Tracy Saxton and is headquartered in Seattle, WA. | Health Technology |
Lengo Therapeutics, Inc.
Lengo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA. | Health Technology |
- Beurs
- Insiders
- Tracy Saxton
- Ervaring
